Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GALNT16 and EXD2 antisense RNA 1 (GALNT16-AS1) is a long non-coding RNA gene transcribed from chromosome 14 on the reverse strand[1]. Antisense RNAs are regulatory molecules that modulate the expression of neighboring or overlapping genes through various mechanisms, including interference with transcription, epigenetic modification, or mRNA stability[2]. There is currently no evidence for GALNT16-AS1 as a therapeutic target or involvement in specific diseases, nor any documented interactions with drugs or function as a biomarker. Its biological relevance likely resides in local gene regulation, potentially affecting expression of adjacent genes such as GALNT16 or EXD2, but experimental data for its specific function is not yet available[1][2].
Not applicable; no targeted drugs known for GALNT16-AS1. Mechanistically, antisense RNAs typically regulate gene expression via transcriptional interference, chromatin modification, or mRNA stability[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GALNT16 and EXD2 antisense RNA 1 (GALNT16-AS1).